

MIPS Seminar Program

Meet the emerging leaders

📅 14 November 2023 ⌚ 12:00 to 1:00 pm 📍 LT3

Dr Amandeep Kaur (*Medicinal Chemistry*)



Fluorescent tools for imaging at the nanoscale

Dr Amandeep Kaur is a Lecturer and ARC DECRA Fellow at the Monash Institute of Pharmaceutical Sciences. She completed her PhD in 2016 at the University of Sydney with Prof. Elizabeth New. She then took up a postdoctoral position in biological imaging at the University of New South Wales. In 2018 she returned to the University of Sydney as a University of Sydney Vice Chancellor's Fellow to establish her independent research career. Dr Kaur holds an Australian Research Council Discovery Early Career Researcher Award. Research in her group is focussed on the development of fluorophores and fluorescent sensors for nanoscale imaging of crucial biomolecular targets for which there is an unmet need.

Dr Stanley Xie (*Drug Delivery Disposition & Dynamics*)



Development of novel antimalarials by targeting the proteasome and aminoacyl-tRNA synthetases

Dr Stanley Xie is an ARC DECRA fellow at the Monash institute of Pharmaceutical Sciences. His current research interests focus on the discovery and development of new antimalarial inhibitors. Stanley completed his PhD in Prof. Leann Tilley's lab at the University of Melbourne in 2016. His postdoctoral research has been aiming to translate his basic research findings into pre-clinical development of potential antimalarial drugs. Stanley has worked with Takeda Pharmaceuticals, GSK and Medicines for Malaria to develop small molecule inhibitors through High Throughput Screen and Hit-to-Lead phases to treat malaria. In 2018, he relocated to the GSK Tres Cantos Open Labs in Spain for half a year to search for novel inhibitors from GSK collections of proprietary compounds. Stanley has authored several papers in leading journals like Science and PNAS, attracting over 1,400 citations. He received the Fred Collins Award (2016) from ASBMB and the Young Scientist Award (2021) from FAOBMB.

Dr Aili Langford (*Centre for Medicine Use and Safety*)



Can we use clinical practice guidelines to deprescribe opioids and reduce medication-related harm?

Dr Aili Langford is a pharmacist and postdoctoral research fellow at the Centre for Medicine Use and Safety (CMUS). Aili's research focuses on reducing medication-related harm through deprescribing (medication dose reduction or cessation). During her PhD at the University of Sydney, Aili led the development of the Evidence-Based Clinical Practice Guideline for Deprescribing Opioid Analgesics, with recommendations approved by the Australian National Health and Medical Research Council (NHRMRC). She is currently working with Dr Emily Reeve (Senior Research Fellow, CMUS), investigating mechanisms to integrate deprescribing recommendations into treatment-focused clinical practice guidelines.